611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA: Taking Medicine for a Cold? Be Mindful of Your HeartStudy Examines Link Between Type 1 Diabetes, Broken BonesDisrupted Sleep Plagues Hospital Patients, But New Program Might HelpStem Cell Therapy Shows Early Promise Against Macular Degeneration1 in 4 Antibiotic Prescriptions Isn't Needed: StudyClimate Change Already Hurting Human Health, Review ShowsGene-Linked Iron Disorder More Common Than ThoughtRace May Matter for Liver Transplant SuccessLife in Space May Take Toll on Spinal MusclesHealth Tip: Understanding a Heart MurmurCalling All Blood Donors …Opioids Now More Deadly for Americans Than Traffic AccidentsWhy Your Heart Needs a Good Night's SleepNature or Nurture? Twins Study Helps Sort Out Genes' Role in DiseaseVaccines: Not Just for KidsExercise Caution to Protect Your Skin at the GymMake Cancer Prevention a Priority in 2019AHA: New Cholesterol Guidelines Put Ethnicity in the SpotlightBroad-Range Ebola Drug Shows Promise in Animal TestsPrescription Opioids May Raise Pneumonia RiskHealth Tip: Prevent Travelers' DiarrheaCancer Patients May Face Greater Risk of ShinglesThyroid Surgery Complications Can Land Some Back in the HospitalRadiation Doses From CT Scans Vary WidelyHealth Tip: Job-Related Chemical Exposure Through the SkinJob Insecurity May Take a Toll on Your HeartPhysical Therapy Can Keep Sports Injuries at BayPersistent Cough May Mean See Your Doctor1 in 10 Adults Have Food Allergies, But Twice as Many Think They DoCatching Up on News About Catch-Up SleepHepatitis C Screening Can Help Prevent Liver DiseaseCan Herbal Drug Kratom Kill?Cholesterol Levels Spike After ChristmasDeadly Meningitis B Targets College StudentsNew Cholesterol Drug's High Price May Not Be Worth It: StudyAsthma Often Goes Undetected in Urban Teens, Study FindsBe Alert for Concussions in Young AthletesHow Seniors Can Prevent Hypothermia This WinterWhopping Numbers on Whooping CoughKidney Disease Risk Tied to Sugar-Sweetened DrinksHealth Tip: Understanding Whooping CoughHealth Tip: Strep Isn't an Ordinary Sore ThroatHolidays' Pitfalls for Those With Food AllergiesWinter's Many Challenges to Eye HealthHeart Risks High in Older Cancer Patients Before DiagnosisCertain Antibiotics Tied to Deadly Heart Vessel Tears: FDAHepatitis C Cases Cluster in States Hit Hard by OpioidsEven Non-Concussion Head Hits Affect Young Football Players' VisionAverage American Getting Fatter, but Not Taller1 in 4 People Over 25 Will Be Hit by Stroke
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA Approves Aimovig to Prevent Migraines


HealthDay News
Updated: May 21st 2018

new article illustration

MONDAY, May 21, 2018 (HealthDay News) -- Aimovig (erenumab-aooe) has been approved by the U.S. Food and Drug Administration to prevent migraine headaches in adults.

Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule involved in migraine attacks, the agency said in a news release.

"Aimovig provides patients with a novel option for reducing the number of days with migraine," Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "We need new treatments for this painful and often debilitating condition."

Aimovig was evaluated in clinical studies involving more than 2,000 people. Over the course of the studies, patients treated with Aimovig experienced, on average, one to two fewer monthly migraine days, compared to participants taking a placebo. The drug's most common side effects included injection-site reactions and constipation.

Aimovig is produced by Amgen Inc., based in Thousand Oaks, Calif.

More Information